We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
+13.67%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$247M
AUM Growth
+$28.4M
Cap. Flow
+$6.96M
Cap. Flow %
2.82%
Top 10 Hldgs %
99.51%
Holding
17
New
4
Increased
1
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$8.5M
2
INSM icon
Insmed
INSM
+$5.71M
3
JUNO
Juno Therapeutics, Inc.
JUNO
+$3.07M
4
LOXO
Loxo Oncology, Inc
LOXO
+$1.11M
5
EPZM
Epizyme, Inc
EPZM
+$891K

Top Sells

Rank Stock Value
1
NSTG
NanoString Technologies, Inc.
NSTG
+$4.2M
2
AIMT
Aimmune Therapeutics
AIMT
+$3.71M
3
DERM
Dermira, Inc.
DERM
+$2.01M
4
AKBA icon
Akebia Therapeutics
AKBA
+$719K
5
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$591K

Sector Composition

Rank Sector Weight
1 Healthcare 26.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AIMT
1
DELISTED
Aimmune Therapeutics
AIMT
$94.7M 38.39%
3,820,462
-172,055
-4% -$3.71M
AERI
2
DELISTED
Aerie Pharmaceuticals
AERI
$81.3M 32.95%
1,672,714
– –
EPZM
3
DELISTED
Epizyme, Inc
EPZM
$29.4M 11.92%
1,543,108
+58,368
+4% +$891K
ALDR
4
DELISTED
Alder Biopharmaceuticals
ALDR
$12.8M 5.18%
1,043,832
– –
INSM icon
5
Insmed
INSM
$23B
$9.36M 3.8%
+300,000
New +$5.71M
XLRN
6
DELISTED
Acceleron Pharma
XLRN
$9.13M 3.7%
+244,756
New +$8.5M
JUNO
7
DELISTED
Juno Therapeutics, Inc.
JUNO
$4.04M 1.64%
+90,000
New +$3.07M
JNCE
8
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.87M 0.76%
119,912
– –
DERM
9
DELISTED
Dermira, Inc.
DERM
$1.58M 0.64%
58,624
-76,670
-57% -$2.01M
LOXO
10
DELISTED
Loxo Oncology, Inc
LOXO
$1.32M 0.53%
+14,300
New +$1.11M
OREX
11
DELISTED
Orexigen Therapeutics, Inc.
OREX
$1.11M 0.45%
523,132
-78,881
-13% -$192K
LRMR icon
12
Larimar Therapeutics
LRMR
$396M
$108K 0.04%
2,565
-7,410
-74% -$308K
AKBA icon
13
Akebia Therapeutics
AKBA
$343M
– –
-50,000
Closed -$719K
ARDX icon
14
Ardelyx
ARDX
$1.26B
– –
-37,500
Closed -$191K
SGMO
15
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-46,000
Closed -$405K
NSTG
16
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-254,015
Closed -$4.2M
BLCM
17
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-5,056
Closed -$591K

Similar funds

AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
MSKCC
Memorial Sloan Kettering Cancer Center New York $24.6M AUM 10.16% 1-Year Est. Return
BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return

Foresite Capital Management II's Q3 2017 Portfolio in Review

As of Q3 2017, Foresite Capital Management II held 17 positions worth $247M, up 13% from $218M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management II's Q3 2017 filing shows 4 new, 1 increased, 4 reduced and 5 closed positions. Its largest new stake was Acceleron Pharma: 244,756 shares worth $9.13M. The largest sale was NanoString Technologies, Inc., an estimated $4.2M.

By sector, the portfolio is most concentrated in Healthcare at 26% of assets, up from 20% a quarter earlier.

  • Foresite Capital Management II's largest Q3 2017 buy was Acceleron Pharma: 244,756 shares worth $9.13M.
  • Foresite Capital Management II added most to Epizyme, Inc in Q3 2017, an estimated $891K increase.
  • Foresite Capital Management II's biggest Q3 2017 reduction was Aimmune Therapeutics, cutting an estimated $3.71M.
  • Foresite Capital Management II fully exited NanoString Technologies, Inc. in Q3 2017, selling an estimated $4.2M.
  • Foresite Capital Management II's ten largest holdings make up 100% of its $247M portfolio in Q3 2017.
  • Foresite Capital Management II opened 4 new positions and closed 5 in Q3 2017.
  • Foresite Capital Management II's portfolio value rose 13% quarter-over-quarter to $247M.

Based on Foresite Capital Management II's 13F filing for Q3 2017, filed 13 Nov 2017.